Merck to phase out osteoporosis specialty team
Merck plans to eliminate its osteoporosis specialty team at the end of the year, ahead of the February 2008 patent expiration of its bone density blockbuster Fosamax.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.